Developing therapeutic antibodies against SARS-CoV-2
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.
Adaptive will extend its high-throughput immune medicine platform to rapidly screen the massive genetic diversity of the B-cell repertoire. This enables us to identify tens of thousands of naturally occurring BCRs from survivors of COVID-19 to characterize the best antibodies that neutralize SARS-CoV-2 and potentially other related coronaviruses. We have identified neutralizing antibody candidates and are in discussions with potential partners to take them forward into development and commercialization.